Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;141(12):2079-95.
doi: 10.1007/s00432-015-1975-5. Epub 2015 Apr 22.

Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities

Judith Niesen  1 , Christoph Stein  2   3 , Hannes Brehm  3 , Grit Hehmann-Titt  4 , Rolf Fendel  2   3 , Georg Melmer  4 , Rainer Fischer  2   5 , Stefan Barth  2   3
Affiliations

Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities

Judith Niesen et al. J Cancer Res Clin Oncol. 2015 Dec.

Abstract

Purpose: The epidermal growth factor receptor (EGFR) is overexpressed in many solid tumors. EGFR-specific monoclonal antibodies (mAbs), such as cetuximab and panitumumab, have been approved for the treatment of colorectal and head and neck cancer. To increase tissue penetration, we constructed single-chain fragment variable (scFv) antibodies derived from these mAbs and evaluated their potential for targeted cancer therapy. The resulting scFv-based EGFR-specific immunotoxins (ITs) combine target specificity of the full-size mAb with the cell-killing activity of a toxic effector domain, a truncated version of Pseudomonas exotoxin A (ETA').

Methods: The ITs and corresponding imaging probes were tested in vitro against four solid tumor entities (rhabdomyosarcoma, breast, prostate and pancreatic cancer). Specific binding and internalization of the ITs scFv2112-ETA' (from cetuximab) and scFv1711-ETA' (from panitumumab) were demonstrated by flow cytometry and for the scFv-SNAP-tag imaging probes by live cell imaging. Cytotoxic potential of the ITs was analyzed in cell viability and apoptosis assays. Binding of the ITs was proofed ex vivo on rhabdomyosarcoma, prostate and breast cancer formalin-fixed paraffin-embedded biopsies.

Results: Both novel ITs showed significant pro-apoptotic and anti-proliferative effects toward the target cells, achieving IC50 values of 4 pM (high EGFR expression) to 460 pM (moderate EGFR expression). Additionally, rapid internalization and specific in vitro and ex vivo binding on patient tissue were confirmed.

Conclusions: These data demonstrate the potent therapeutic activity of two novel EGFR-specific ETA'-based ITs. Both molecules are promising candidates for further development toward clinical use in the treatment of various solid tumors to supplement the existing therapeutic regimes.

Keywords: Cancer therapy; Epidermal growth factor receptor (EGFR); Immunotoxin (IT); Pseudomonas exotoxin A (ETA′); SNAP-tag; Single-chain fragment variable (scFv).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bioconjug Chem. 2009 May 20;20(5):1010-5 - PubMed
    1. Annu Rev Med. 2007;58:221-37 - PubMed
    1. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10 ):1926-34 - PubMed
    1. Clin Cancer Res. 2012 Nov 1;18(21):6049-57 - PubMed
    1. Br J Haematol. 2010 Mar;148(6):879-89 - PubMed

Publication types

MeSH terms

LinkOut - more resources